Tolhurst Noall’s Biotech guru Martin Ashdown has an
eight page bit of research out on Chemeq. Biotech valuations are all
about assumptions and probability and a bit of hope. With that in mind
….he says that “provided Chemeq continues to deliver, an August
revised value per share of $20.30 is a conservative estimate from a
projected 10% global market penetration”.